Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W1HM
|
|||
| Former ID |
DIB020486
|
|||
| Drug Name |
nafadotride
|
|||
| Synonyms |
Nafadotride; 149649-22-9; (+-)-nafadotride; N-[(1-BUTYL-2-PYRROLIDINYL)METHYL]-4-CYANO-1-METHOXY-2-NAPHTHALENECARBOXAMIDE; N-[(1-butylpyrrolidin-2-yl)methyl]-4-cyano-1-methoxynaphthalene-2-carboxamide; CHEMBL286252; CHEBI:64191; A1-01951; SMR000466292; AC1MPBUT; GTPL44; MLS000758952; MLS001424218; SCHEMBL635866; DTXSID1042603; CTK8H0240; MolPort-023-276-076; HMS3394A15; HMS3267P15; HMS2232B11; HMS2052A15; HMS3370D02; BCP27779; BDBM50133923; AKOS024257976; TRA0072321; CCG-101119; NC00369; SAM001247092; CPD000466292; LS-186981; LS-187623
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C22H27N3O2
|
|||
| Canonical SMILES |
CCCCN1CCCC1CNC(=O)C2=C(C3=CC=CC=C3C(=C2)C#N)OC
|
|||
| InChI |
1S/C22H27N3O2/c1-3-4-11-25-12-7-8-17(25)15-24-22(26)20-13-16(14-23)18-9-5-6-10-19(18)21(20)27-2/h5-6,9-10,13,17H,3-4,7-8,11-12,15H2,1-2H3,(H,24,26)
|
|||
| InChIKey |
IDZASIQMRGPBCQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 149649-22-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
4546259, 7980060, 9949320, 14877084, 26719799, 36278386, 46387001, 49681626, 50070521, 50071159, 53746209, 56311648, 57309748, 57356263, 85209195, 85789022, 92308559, 103195448, 104024628, 112212992, 124659097, 124800019, 125666021, 128154304, 135305572, 135610838, 135650679, 135698262, 139676272, 144235422, 162022313, 162023065, 163145133, 163751395, 172080492, 178125929, 179296009, 179323700, 184538718, 202558049, 219812685, 226935689, 241182349, 249617290, 252126122, 252270535, 252360576
|
|||
| ChEBI ID |
CHEBI:64191
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 44). | |||
| REF 2 | Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. | |||
| REF 3 | Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther. 1995 Dec;275(3):1239-46. | |||
| REF 4 | Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. Mol Pharmacol. 2000 Jan;57(1):144-52. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.